Select publications

Cannon GM Jr et al. Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. Urology 2003;62 Suppl 1:2-8. Abstract

D’Amico AV et al. Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol 2003;170(6 Pt 2):S42-6. Abstract

D’Amico AV et al. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst 2004;96(7):509-15. Abstract

D’Amico AV et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351(2):125-35. Abstract

D’Amico AV et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004;292(7):821-7. Abstract

D’Amico AV et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95(18):1376-83. Abstract

Dreicer R. Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomy. Cancer Treat Rev 2002;28(4):189-94. Abstract

Eastham JA et al; Polyp Prevention Trial Study Group. Variation of serum prostate-specific antigen levels: An evaluation of year-to-year fluctuations. JAMA 2003;289(20):2695-700. Abstract

Johnstone PA et al. The 100-day PSA: Usefulness as surrogate end point for biochemical diseasefree survival after definitive radiotherapy of prostate cancer. Prostate Cancer Prostatic Dis 2004;7(3):263-7. Abstract

Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin North Am 2003;30(2):219-26. Abstract

Loberg RD et al. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology 2003;62 Suppl 1:128-33. Abstract

Moul JW. Variables in predicting survival based on treating “PSA-only” relapse. Urol Oncol 2003;21(4):292-304. Abstract

Moul JW et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004;171(3):1141-7. Abstract

Pollack A et al. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;57(1):19-23. Abstract

Pound CR et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7. Abstract

Roobol MJ et al. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: Results of second screening round of ERSPC (ROTTERDAM). Urology 2004;63(2):309-13. Abstract